Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing
March 08, 2021 03:00 ET | Cytovance Biologics
OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and...
22157.jpg
Global Viral Vector & Plasmid DNA Manufacturing Market Report 2021 - Rising Use of Viral Vectors in Several Treatments Demands Developments in Plasmids and Vectors
February 17, 2021 05:48 ET | Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Workflow, by Application, by End User - Global Forecast to 2025 -...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics announces Regulatory Strategies for Gene Therapy Product Development webinar
February 08, 2021 03:00 ET | Cytovance Biologics
OKLAHOMA CITY, Okla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene...
22157.jpg
Global Viral Vector and Plasmid DNA Manufacturing Market Trends & Forecasts Report 2020-2025: Explore the Potential Applications in Novel Drug Delivery Approaches
December 30, 2020 05:23 ET | Research and Markets
Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics Announces an Investment in Mass Spectrometry Services
July 15, 2020 03:00 ET | Cytovance Biologics
OKLAHOMA CITY, July 15, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics Promotes John Mott to Vice President of Development
July 13, 2020 03:00 ET | Cytovance Biologics
OKLAHOMA CITY, July 13, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the promotion of Dr. John...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics Promotes Dr. Jesse McCool to Chief Executive Officer
March 30, 2020 03:00 ET | Cytovance Biologics
OKLAHOMA CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Jesse...
Aldevron Adds DasherGFP® mRNA to its Product Portfolio
February 12, 2020 10:30 ET | Aldevron
Fargo, N.D., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, announced...
Aldevron Plasmids Used to Support Calviri’s Clinical Trial of a Vaccine Against Canine Cancer
December 03, 2019 09:51 ET | Aldevron
TEMPE, A.Z. and FARGO, N.D., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Prevention of cancer onset is the ultimate aspiration for animals and humans. Cancer is caused by mutations that are specific to the...
Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing
October 22, 2019 07:00 ET | Aldevron
Fargo, N.D, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aldevron has announced the immediate availability of Nanoplasmids™ and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through...